Science Enterprises Plc Oxford Purchases 200,000 Shares of PepGen (NASDAQ:PEPG) Stock

Key Points

• Science Enterprises Plc Oxford has acquired 200,000 shares of PepGen, Inc. at a price of $3.20 per share, totaling $640,000, which increases their ownership stake by 4.21%.
• PepGen's stock performance has been notable, trading at $4.67, with a market cap of $153.04 million and analysts forecasting a consensus rating of "Moderate Buy."
• Recent analyst reports have resulted in price target increases for PepGen, with Wedbush raising it from $7.00 to $9.00 and Stifel Nicolaus from $9.00 to $12.00.

PepGen, Inc. (NASDAQ:PEPG - Get Free Report) major shareholder Science Enterprises Plc Oxford acquired 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 30th. The stock was bought at an average price of $3.20 per share, with a total value of $640,000.00. Following the completion of the acquisition, the insider directly owned 4,955,388 shares of the company's stock, valued at $15,857,241.60. This trade represents a 4.21% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

PepGen Price Performance

NASDAQ PEPG traded up $0.05 on Wednesday, reaching $4.67. The company had a trading volume of 2,946,726 shares, compared to its average volume of 2,081,737. The firm has a market cap of $153.04 million, a price-to-earnings ratio of -1.57 and a beta of 1.17. PepGen, Inc. has a fifty-two week low of $0.88 and a fifty-two week high of $9.94. The business has a 50 day moving average of $1.71 and a two-hundred day moving average of $1.52.

PepGen (NASDAQ:PEPG - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.15. As a group, research analysts predict that PepGen, Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on PEPG shares. Wedbush upped their price target on shares of PepGen from $7.00 to $9.00 and gave the company an "outperform" rating in a research report on Thursday, September 25th. Stifel Nicolaus upped their target price on shares of PepGen from $9.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday, September 25th. HC Wainwright lifted their target price on shares of PepGen from $8.00 to $12.00 and gave the stock a "buy" rating in a research report on Thursday, September 25th. Finally, Guggenheim restated a "buy" rating and set a $6.00 price target on shares of PepGen in a research note on Wednesday, September 24th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $8.40.

Institutional Trading of PepGen

A number of hedge funds have recently made changes to their positions in PEPG. Bank of America Corp DE lifted its holdings in shares of PepGen by 54.7% during the 4th quarter. Bank of America Corp DE now owns 53,868 shares of the company's stock worth $204,000 after acquiring an additional 19,056 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of PepGen by 442.5% during the 4th quarter. Deutsche Bank AG now owns 44,735 shares of the company's stock worth $170,000 after acquiring an additional 36,489 shares during the last quarter. Millennium Management LLC lifted its stake in PepGen by 1,033.2% in the fourth quarter. Millennium Management LLC now owns 156,636 shares of the company's stock worth $594,000 after purchasing an additional 142,814 shares during the last quarter. Wellington Management Group LLP lifted its stake in PepGen by 17.2% in the fourth quarter. Wellington Management Group LLP now owns 47,506 shares of the company's stock worth $180,000 after purchasing an additional 6,989 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in PepGen in the first quarter worth $25,000. 58.01% of the stock is owned by institutional investors.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.